← All trials
NCT04301154
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Jan 31, 2021
- Completion date
- Sep 30, 2021
- First posted
- Mar 10, 2020
- Last posted
- Mar 10, 2020
- Enrollment
- 45
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Henry M. Jackson Foundation for the Advancement of Military MedicineLead sponsor
- Henry M. Jackson Foundation for the Advancement of Military MedicineStudy chair
- PENTA FoundationCollaborator
- United States ArmyCollaborator
- Bambino Gesù Hospital and Research InstituteCollaborator
- Case Western Reserve UniversityCollaborator
- Chulalongkorn UniversityCollaborator
- Johns Hopkins UniversityCollaborator
- University of MiamiCollaborator
- University of PadovaCollaborator
- Karolinska InstituteCollaborator
- LeidosCollaborator
- Government of ThailandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.